Clinical trials · New Jersey
Renal Cancer clinical trials in New Jersey
We’re tracking 21 recruiting renal cancer studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
New Brunswick, New JerseyAges 12 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Toms River, New JerseyAges 18 years+ - NCT07227415RecruitingPhase 1/Phase 2
Study of a new drug for advanced kidney cancer
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Montvale, New JerseyAges 18 years+ - NCT00582621Recruiting
Family history study to support genetic testing research
This study collects family and medical history to better understand inherited causes of blood cancers (like lymphoma) and related conditions. It may help researchers build genetic findings that could improve how families understand their risk and future care.
Middletown, New JerseyAges Any age - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Basking Ridge, New JerseyAges 18 years+ - NCT06792552RecruitingPhase 1
Study of SIM0505 for advanced solid tumors
This trial tests a new drug called SIM0505 for people with advanced solid tumors that have not responded to standard treatments. The study looks at different cancer types, including ovarian cancer, kidney cancer, uterine cancer, and lung cancer, to see if SIM0505 can help shrink tumors or slow their growth.
Hackensack, New JerseyAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Montvale, New JerseyAges 18 years+ - NCT02087852Recruiting
Kidney cancer DNA registry for patients and family
This study collects DNA from adults with kidney cancer (or suspected kidney cancer), plus DNA from some family members and healthy controls. It helps researchers understand whether certain genetic changes might be linked to kidney cancer risk.
Basking Ridge, New JerseyAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
New Brunswick, New JerseyAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Toms River, New JerseyAges 18 years+ - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Hackensack, New JerseyAges 18 years+ - NCT05874921Recruiting
Registry for adults with UTUC treated with Jelmyto
This registry collects information about adults with upper tract urothelial cancer (UTUC) who received Jelmyto after it was approved. It helps doctors understand outcomes and real-world experience with Jelmyto.
New Brunswick, New JerseyAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Hackensack, New JerseyAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
East Brunswick, New JerseyAges 18 years+ - NCT06699602RecruitingPhase 2
Immunotherapy before kidney surgery for high-risk kidney cancer
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
Basking Ridge, New JerseyAges 18 years+ - NCT06835972RecruitingPhase 1/Phase 2
Abemaciclib and cabozantinib for advanced kidney cancer
This trial tests a new combination of two oral drugs (abemaciclib and cabozantinib) for people with advanced kidney cancer (clear cell type) who have already tried at least two other treatments, including an immunotherapy and a targeted therapy, but their cancer kept growing. The goal is to see if this combination can shrink tumors or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
East Brunswick, New JerseyAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Hackensack, New JerseyAges 18 years+ - NCT06083922RecruitingPhase 2
CyBorD plus Daratumumab for kidney disease caused by abnormal proteins
This trial tests a combination of four drugs (CyBorD plus daratumumab) to treat kidney damage caused by abnormal proteins (monoclonal gammopathy). It aims to improve kidney function and reduce protein levels.
Basking Ridge, New JerseyAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Basking Ridge, New JerseyAges 18 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting renal cancer studies listed above.
- Memorial Sloan Kettering Monmouth · 12 studies
- Memorial Sloan Kettering Basking Ridge · 11 studies
- Memorial Sloan Kettering Bergen · 11 studies
- Rutgers Cancer Institute of New Jersey · 7 studies
- Hackensack University Medical Center · 5 studies
- Community Medical Center · 4 studies
- Cooperman Barnabas Medical Center · 3 studies
- Jefferson Cherry Hill Hospital · 3 studies
What taking part in a renal cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Renal Cancer trials in other states
Common questions
- Are there renal cancer clinical trials in New Jersey?
- Yes. We're currently tracking 21 recruiting renal cancer studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a renal cancer study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a renal cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New renal cancer studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.